Literature DB >> 2533074

Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.

N P Chau1, I Pithois-Merli, J Levenson, A C Simon.   

Abstract

The effects of ketanserin (40 mg p.o.) on blood pressure and brachial haemodynamics (brachial artery diameter, brachial blood velocity and blood flow) have been compared in a double-blind study with those of ritanserin (10 mg p.o.) and placebo. Haemodynamic parameters were measured before and 1 h after treatment. Patients with mild to moderate essential hypertension participated in this study, 6 each on ketanserin, ritanserin and placebo. Placebo significantly reduced heart rate and did not modify the other parameters. Compared to placebo, ketanserin significantly reduced systolic and diastolic blood pressure, increased brachial blood velocity and flow, and decreased forearm vascular resistance. Compared to placebo, ritanserin slightly decreased blood pressure and slightly increased blood flow, but neither effect was significant. When blood circulation to the hand was excluded, neither ketanserin nor ritanserin modified the proximal arterial resistance or blood flow. It is concluded that the actions of ketanserin and ritanserin essentially occurred in the distal part of the upper limb, and alpha 1-receptor blockade is probably involved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533074     DOI: 10.1007/bf00679772

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Brachial artery hemodynamic response to acute converting enzyme inhibition by enalaprilat in essential hypertension.

Authors:  A C Simon; N P Chau; J Levenson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

2.  Mechanism of antihypertensive action of ketanserin in man.

Authors:  I W Reimann; J C Frölich
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

3.  The mechanism of the antihypertensive effects of ketanserin: a comparison with metoprolol.

Authors:  E Casiglia; R Gava; A Semplicini; P Nicolin; A C Pessina
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

4.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

5.  Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle.

Authors:  M L Cohen; R W Fuller; K S Wiley
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

6.  Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468).

Authors:  J M Van Nueten; P A Janssen; A De Ridder; P M Vanhoutte
Journal:  Eur J Pharmacol       Date:  1982-02-05       Impact factor: 4.432

Review 7.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.

Authors:  P Vanhoutte; A Amery; W Birkenhäger; A Breckenridge; F Bühler; A Distler; J Dormandy; A Doyle; E Frohlich; L Hansson
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

8.  Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.

Authors:  L A Ferrara; M L Fasano; S Soro; P Rubba; A Iannuzzi
Journal:  J Clin Pharmacol       Date:  1985-04       Impact factor: 3.126

9.  The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.

Authors:  D J Stott; A R Saniabadi; J Hosie; G D Lowe; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Regional vascular effects of serotonin and ketanserin in young, healthy subjects.

Authors:  G J Blauw; P van Brummelen; P C Chang; P Vermeij; P A van Zwieten
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.